Inactive Instrument

All News MOUN CRES Nasdaq

Equities

MCADU

US62402D2045

All News

Unlock all the news: Be the first to know and act before the market!

MOUN CRES : Statement of Changes in Beneficial Ownership - Form 4	19/22/19	PU
MOUN CRES : Statement of Changes in Beneficial Ownership - Form 4	16/22/16	PU
MOUN CRES : Statement of Changes in Beneficial Ownership - Form 4	15/22/15	PU
MOUN CRES : Better Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Form 8-K	11/22/11	PU
MOUN CRES : Better Therapeutics Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results Following the Earlier Announcement of Positive Primary Endpoint Results - Form 8-K	28/22/28	PU
MOUN CRES : Better Therapeutics Appoints Frank Karbe as Chief Executive Officer - Form 8-K	07/22/07	PU
MOUN CRES : Better Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results - Form 8-K	28/22/28	PU
MOUN CRES : KOL Call Discussing Better Tx's Top Line Results for BT-001 283.3 KB	23/22/23	PU
MOUN CRES : MARCH 15, 2022 Primary Endpoint Day 90 Analysis Better+ THERAPEUTICS - Form 8-K/A	16/22/16	PU
MOUN CRES : Better Therapeutics Announces Positive Primary Endpoint Data from Pivotal Clinical Trial of BT-001, a Prescription Digital Therapeutic (PDT) for Patients with Uncontrolled Type 2 Diabetes - Form 8-K	15/22/15	PU
MOUN CRES : Amendment to Current Report (Form 8-K/A)	15/22/15	PU
Employee Spotlight: Michelle Gearhart	16/21/16	PU
MOUN CRES : UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS - Form 8-K/A	26/21/26	PU
Mountain Crest Acquisition Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	23/21/23	CI
MOUN CRES : Better Therapeutics Completes Enrollment of Pivotal Trial for BT-001, a Prescription Digital Therapeutic for Type 2 Diabetes - Form 8-K	18/21/18	PU
MOUN CRES : Better Therapeutics Appoints Major General Elder Granger, M.D., U.S. Army (retired) to its Board of Directors - Form 8-K	18/21/18	PU
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS - Form 8-K	04/21/04	PU
BETTER THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Amendment or Waiver to Code of Ethics, Change in Shell Company Status, Financial Statements and Exhibits (form 8-K)	04/21/04	AQ
Mass General Brigham Joins Better Therapeutics in Real World Evidence Study Collaboration	02/21/02	BU
Better Therapeutics Closes Business Combination and Debuts on Nasdaq	29/21/29	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News MOUN CRES Nasdaq

Equities

MCADU

US62402D2045

All News

Filters